Our Pricing

Your Complete Wegovy Starter Dose Schedule From £79.00

Understanding the wegovy starter dose schedule uk protocol is essential for safe, effective weight management. At Cured Pharmacy, our UK-registered clinical team guides you through each dose escalation step, from the initial 0.25mg pen to the full 2.4mg maintenance dose, with transparent pricing from £79.00 and ongoing prescriber support throughout your treatment journey.

How the Wegovy Starter Dose Schedule Works

Wegovy (semaglutide) follows a carefully structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The wegovy starter dose schedule uk begins at 0.25mg once weekly for four weeks, then increases gradually every four weeks until reaching the maintenance dose of 2.4mg [1].

This titration approach allows your body to adapt to semaglutide's GLP-1 receptor activity, which slows gastric emptying and reduces appetite. In the STEP 1 clinical trial, participants following this exact dosing schedule achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. The gradual escalation significantly reduces the incidence of nausea and vomiting compared to starting at higher doses.

Each Wegovy pen contains a fixed dose for one injection, eliminating dosing errors. You'll receive a new pen strength as you progress through the schedule, with your UK prescriber monitoring your response and adjusting the timeline if needed based on tolerability and clinical assessment.

Complete Wegovy Dose Escalation Timeline

The standard wegovy dosing schedule uk follows a 20-week escalation period before reaching the full therapeutic dose. Weeks 1-4 use the 0.25mg starter pen, followed by 0.5mg for weeks 5-8. At week 9, you'll progress to 1.0mg, then 1.7mg at week 13, finally reaching the 2.4mg maintenance dose at week 17 [2].

This precise schedule is based on pharmacokinetic data showing semaglutide reaches steady-state concentrations after approximately 4-5 weeks at each dose level. Your UK prescriber may extend any dose tier by an additional four weeks if you experience persistent gastrointestinal symptoms, ensuring tolerability without compromising long-term efficacy.

Most patients remain on the 2.4mg maintenance dose indefinitely, as clinical trials demonstrate continued weight management benefits with ongoing treatment. However, some individuals achieve optimal results at the 1.7mg dose, particularly those with lower starting BMI or significant side effects at higher strengths.

What to Expect at Each Dose Level

During the 0.25mg and 0.5mg starter phases, you may notice reduced appetite and smaller portion sizes, though significant weight loss typically begins at the 1.0mg dose and beyond. Mild nausea affects approximately 20-44% of patients during dose escalation but usually resolves within 2-3 days as your body adjusts [1].

The 1.7mg and 2.4mg doses deliver the most substantial weight loss effects, with trial data showing peak efficacy at the full maintenance dose. Your UK prescriber will schedule follow-up assessments every 8-12 weeks to monitor progress, adjust dosing if needed, and ensure you're achieving clinically meaningful weight reduction of at least 5% within 12-16 weeks of starting treatment [2].

Wegovy Starter Dose Schedule UK: Managing Side Effects

Gastrointestinal symptoms represent the most common side effects during the wegovy starter dose schedule, with nausea (44%), diarrhoea (30%), and constipation (24%) reported most frequently in clinical trials [1]. These effects peak during the first 2-3 days after each dose increase and typically diminish with continued use at the same strength.

To minimise discomfort, eat smaller, more frequent meals rather than large portions, avoid high-fat foods that delay gastric emptying further, and stay well-hydrated throughout the day. If nausea persists beyond one week at any dose tier, contact your UK prescriber before your next injection—they may recommend extending that dose level for an additional four weeks rather than escalating on schedule.

Serious side effects are rare but require immediate medical attention. These include severe abdominal pain (potential pancreatitis), visual changes, persistent vomiting leading to dehydration, or signs of thyroid tumours such as neck lumps or difficulty swallowing. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment, with direct access to UK prescribers if concerns arise between scheduled reviews.

Wegovy vs Mounjaro: Comparing Dose Schedules

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) require gradual dose escalation, but their schedules differ significantly. Wegovy's 20-week titration to 2.4mg maintenance contrasts with Mounjaro's 20-week escalation to either 10mg or 15mg, depending on individual response and tolerability.

Mounjaro's dual GIP/GLP-1 receptor mechanism produces greater average weight loss in head-to-head trials—approximately 22.5% body weight reduction with the 15mg dose versus 14.9% with Wegovy 2.4mg over similar timeframes [3]. However, this comes with a higher incidence of gastrointestinal side effects during dose escalation, particularly at the 10mg and 15mg tiers.

Your UK prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, previous GLP-1 experience, and budget considerations. Some patients start with Wegovy's established dosing schedule and switch to Mounjaro if they plateau, whilst others begin with Mounjaro for more aggressive weight reduction targets, subject to clinical assessment and prescriber approval.

Choosing Between Semaglutide and Tirzepatide

If you've previously used daily liraglutide injections or have well-controlled type 2 diabetes, Wegovy's single-pathway GLP-1 mechanism may provide sufficient efficacy with fewer side effects. Patients seeking maximum weight loss outcomes or those who didn't achieve targets with semaglutide may benefit from Mounjaro's dual-receptor activity, though this requires careful monitoring during dose escalation.

Cost also influences treatment choice. Wegovy starts from £79.00 at Cured Pharmacy, making it more accessible for long-term weight management programmes. Both medications require ongoing prescription and clinical review every 8-12 weeks to ensure continued appropriateness and efficacy, with UK prescribers adjusting treatment plans based on individual response and tolerability.

How to Start Your Wegovy Dose Schedule at Cured Pharmacy

Beginning treatment requires a clinical assessment by one of our UK-registered prescribers, which takes under three minutes to complete online. You'll provide your medical history, current medications, weight management goals, and any previous experience with GLP-1 treatments. Our clinical team reviews your assessment within 24 hours and determines whether Wegovy is appropriate and safe for you.

If approved, your prescription is issued electronically and dispensed from our UK-registered pharmacy (GPhC 9012511). Your first supply includes the 0.25mg starter pens with detailed injection instructions and a dose escalation schedule personalised to your treatment plan. We arrange discreet next-day delivery in 100% plain packaging, with no external branding or medication details visible.

Ongoing prescriptions are managed through scheduled reviews every 8-12 weeks, ensuring you progress through the dose schedule safely and achieve clinically meaningful weight loss. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols, and you'll have direct access to our UK prescribers if questions or concerns arise between reviews. Pricing remains transparent throughout—you'll see exact costs before completing your consultation, with no hidden fees or subscription charges.

Maximising Results During Your Wegovy Starter Dose Schedule

Whilst Wegovy significantly reduces appetite and promotes weight loss independently, combining treatment with structured lifestyle modifications enhances outcomes. Clinical trial participants who followed a reduced-calorie diet (500kcal daily deficit) and increased physical activity to 150 minutes weekly achieved 15-20% greater weight loss than those relying on medication alone [2].

Focus on protein-rich foods to preserve lean muscle mass during weight reduction, as GLP-1 treatments can cause both fat and muscle loss if dietary protein intake is insufficient. Aim for 1.2-1.6g protein per kilogram of ideal body weight daily, distributed across meals to optimise satiety and metabolic rate. Resistance training 2-3 times weekly further protects muscle tissue and improves body composition beyond scale weight alone.

Track your progress using multiple metrics rather than body weight exclusively. Measure waist circumference, take progress photographs every four weeks, and monitor improvements in comorbid conditions such as blood pressure, HbA1c, or lipid profiles. These objective markers often improve before significant scale changes occur, particularly during the lower starter doses, and provide motivation to continue through the full escalation schedule.

When to Expect Visible Weight Loss Results

Most patients notice initial weight reduction during weeks 5-8 at the 0.5mg dose, with more substantial changes occurring from week 9 onwards as doses increase to 1.0mg and beyond. Clinical trials show the majority of weight loss occurs between weeks 12-52, with continued gradual reduction through week 68 on the 2.4mg maintenance dose [1].

Your UK prescriber will assess progress at 12-16 weeks into treatment. NICE guidelines recommend discontinuing GLP-1 therapy if you haven't achieved at least 5% body weight reduction by this timepoint, as continued treatment is unlikely to produce clinically meaningful outcomes [2]. However, most patients following the complete wegovy dose schedule uk protocol exceed this threshold, with average reductions of 10-15% by week 20 when reaching maintenance dosing.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, diet, and physical activity levels.